Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > Ringworm Treatment Market

Ringworm Treatment Market Trends

Report ID: GMI6339
Published Date: Jul 2023
Report Format: PDF

Download Free Sample

Ringworm Treatment Market Trends

Ringworm is a highly contagious fungal infection of the skin, scalp, & nails and affects millions of individuals across the globe. Several factors have contributed to the rise in ringworm cases, including growing urbanization, crowded living conditions, inadequate sanitation, and a rise in the number of immunocompromised individuals. The lifestyle changes such as increased participation in sports and recreational activities, have also led to a higher risk of transmission.

Therefore, as the incidence of ringworm continues to climb, the demand for effective and innovative treatment solutions has surged. As a result, pharmaceutical companies and healthcare providers have been investing significantly in research and development to introduce novel antifungal drugs and advanced therapies, thereby leading to a promising growth trajectory for the market.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Ringworm treatment industry was worth USD 13.9 billion in 2022 and is expected to reach USD 21.3 billion by 2032 driven by the rising demand for effective treatment options due to the high prevalence of ringworm infections.

The antifungals segment held 77.8% of the ringworm treatment market share in 2022 and is expected to expand at notable CAGR from 2023-2032 attributed to the continuous development of advanced and innovative formulations that cater to diverse patient needs.

North America ringworm treatment industry generated USD 6 billion in revenue in 2022 and is anticipated to witness 4.3% CAGR from 2023 – 2032 owing to the presence of robust healthcare infrastructure and advanced medical facilities in the region.

Some of the top firms operating in the ringworm treatment industry are Perrigo Company plc, Novartis AG, GlaxoSmithKline Plc, Teva Pharmaceutical Industries Ltd., GLENMARK PHARMACEUTICALS LTD., Pfizer Inc., Sanofi S.A., Merck & Co., Inc., Bayer AG, Gilead Sciences, Inc., and Eli Lilly and Company,